Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2.66 per share in its forthcoming report, representing a decline of 5% year over year. Revenues are projected to reach $25.37 billion, increasing 5.8% from the same quarter last year.
Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Johnson & Johnson metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus among analysts is that 'Sales- Innovative Medicine- WW' will reach $16.59 billion. The estimate indicates a year-over-year change of +6.6%.
The consensus estimate for 'Sales- MedTech- Orthopaedics- Trauma- WW' stands at $831.48 million. The estimate indicates a year-over-year change of +4.9%.
The average prediction of analysts places 'Sales- MedTech- Orthopaedics- Spine, Sports & Other- WW' at $700.77 million. The estimate suggests a change of +0.4% year over year.
According to the collective judgment of analysts, 'Sales- MedTech- Surgery- Advanced- WW' should come in at $1.17 billion. The estimate suggests a change of +0.7% year over year.
It is projected by analysts that the 'Sales- Innovative Medicine- Oncology- CARVYKTI- WW' will reach $708.49 million. The estimate points to a change of +35.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Sales- Innovative Medicine- Neuroscience- SPRAVATO- WW' should arrive at $612.16 million. The estimate points to a change of +33.4% from the year-ago quarter.
Analysts expect 'Sales- MedTech- Cardiovascular- Other Cardiovascular- WW' to come in at $95.46 million. The estimate points to a change of +0.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- MedTech- Cardiovascular- ABIOMED- WW' of $430.98 million. The estimate indicates a year-over-year change of +1.9%.
The combined assessment of analysts suggests that 'Sales- International' will likely reach $10.77 billion. The estimate indicates a year-over-year change of +4.7%.
Analysts predict that the 'Sales- MedTech- Cardiovascular- Electrophysiology- WW' will reach $1.50 billion. The estimate indicates a change of +6% from the prior-year quarter.
Analysts forecast 'Sales- MedTech- Orthopaedics- Hips- US' to reach $273.79 million. The estimate points to a change of +4.5% from the year-ago quarter.
Analysts' assessment points toward 'Organic Sales Growth (Operational growth)' reaching 6.8%. The estimate compares to the year-ago value of 5.4%.
View all Key Company Metrics for Johnson & Johnson here>>>Shares of Johnson & Johnson have experienced a change of -3.2% in the past month compared to the +1.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), JNJ is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).